IDEA AG is a privately held biopharmaceutical company with headquarters in Munich, Germany. IDEA develops and commercialises non-invasive, targeted therapeutics based on stable, ultra-deformable carriers that are typically applied on the skin. These proprietary carriers are driven through the skin barrier by the local water gradient and can be engineered to achieve a high, localised drug concentration at the site of application and deep below. This method of application can diminish the local or systemic adverse side effects of a drug, and often increase its potency. To date, 44 patents from 8 patent families have been granted to the Company to protect its technology.
